Sophia Genetics SA (SOPH) — Cash Flow-to-Debt Ratio
Sophia Genetics SA (SOPH) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of $-8.79 Million could theoretically repay 0% of its total liabilities ($102.77 Million) in one year. See Sophia Genetics SA (SOPH) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sophia Genetics SA Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Sophia Genetics SA across 6 annual periods. Also explore SOPH shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sophia Genetics SA (2019–2024)
Year-by-year debt coverage analysis for Sophia Genetics SA. For market capitalisation and broader financial context, see SOPH company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.73x | $-42.82 Million | $58.82 Million | ▲ +18.0% |
| 2023 | -0.89x | $-48.58 Million | $54.71 Million | ▲ +44.6% |
| 2022 | -1.60x | $-70.09 Million | $43.71 Million | ▼ -23.9% |
| 2021 | -1.29x | $-57.94 Million | $44.77 Million | ▼ -28.9% |
| 2020 | -1.00x | $-31.73 Million | $31.61 Million | ▲ +6.8% |
| 2019 | -1.08x | $-31.68 Million | $29.40 Million | — |